Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.880
-0.058 (-1.17%)
At close: Sep 12, 2025, 4:00 PM EDT
5.05
+0.17 (3.48%)
After-hours: Sep 12, 2025, 5:12 PM EDT

Company Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease.

It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.

The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.

Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Limited
Alterity Therapeutics logo
CountryAustralia
Founded1997
IndustryBiotechnology
SectorHealthcare
Employees9
CEODavid Stamler

Contact Details

Address:
350 Collins Street, Suite 4
Melbourne, VIC 3000
Australia
Phone61 3 9349 4906
Websitealteritytherapeutics.com

Stock Details

Ticker SymbolATHE
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyAUD
CIK Code0001131343
CUSIP Number02155X106
ISIN NumberUS02155X2053
SIC Code2834

Key Executives

NamePosition
Dr. David A. Stamler M.D.Chief Executive Officer
Geoffrey Paul Kempler B.Sc.Co-Founder and Non-Executive Chairman
Abby Macnish Niven B.Com., B.Sc., C.F.A.Chief Financial Officer and Company Secretary
Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of Research and Development Advisory Board
Dr. Steven D. Targum M.D.Chief Medical Advisor
Dr. Robert ChernyHead of Research

Latest SEC Filings

DateTypeTitle
Sep 8, 20256-KReport of foreign issuer
Sep 8, 20256-KReport of foreign issuer
Sep 4, 20256-KReport of foreign issuer
Sep 2, 20256-KReport of foreign issuer
Sep 2, 20256-KReport of foreign issuer
Sep 2, 20256-KReport of foreign issuer
Aug 29, 202520-FAnnual and transition report of foreign private issuers
Aug 22, 20256-KReport of foreign issuer
Aug 15, 20256-KReport of foreign issuer
Aug 15, 20256-KReport of foreign issuer